Merova is rituximab, the difference between otuzumab and rituximab are different indications, different side effects, different immunogenicity, etc..
1. Different indications: otuzumab is used in combination with chemotherapy for primary stage II follicular lymphoma or stage III or IV follicular lymphoma with large masses, and can be used as maintenance therapy for those who have achieved partial remission or above efficacy; rituximab is suitable for chemotherapy-resistant or relapsed inert B-cell non-Hodgkin’s lymphoma.
2. Different side effects: the side effects of otolizumab include infusion reaction, leukopenia, thrombocytopenia, anemia, fever, etc., the use of which should pay attention to the infusion reaction and be prohibited for those who are allergic to it; the side effects of rituximab include infusion reaction, postural hypotension, abdominal pain, abdominal distension, hyperglycemia, etc., the use of which should also pay attention to the infusion reaction and monitoring of blood pressure, and be prohibited for those who are allergic to it.
3. Different immunogenicity: Otuzumab is a humanized monoclonal antibody with low immunogenicity and reduced allergic reactions; Rituximab is a human-mouse chimeric monoclonal antibody with relatively high immunogenicity and relatively high incidence of allergic reactions.
In addition to the above differences, there are other differences between Ortuzumab and Rituximab, such as the higher affinity of Ortuzumab for effector cells than Rituximab, and the lower complement-dependent cytotoxicity of Ortuzumab compared to Rituximab, so it is recommended that patients choose the right drug and treatment for themselves under the guidance of their doctors.